ProCE Banner Activity

HERTHENA-Lung01: Intracranial Results From a Phase II Trial of HER3-DXd in Previously Treated Patients With Advanced EGFR-Mutated NSCLC

Conference Coverage
Slideset

HER3-DXd showed preliminary evidence of CNS activity in patients with locally advanced EGFR-mutated NSCLC who were previously treated with EGFR TKIs and platinum-based chemotherapy.

Released: October 23, 2023

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Inc., Exelixis, Inc., Gilead Sciences, Inc., Lilly and Regeneron Pharmaceuticals, Inc.

AstraZeneca

Bristol Myers Squibb

Daiichi Sankyo, Inc.

Exelixis, Inc.

Gilead Sciences, Inc.

Lilly

Regeneron Pharmaceuticals, Inc